These occur in 20–30% of melanoma patients and are mutually exclusive with BRAF mutations [1], except in resistant melanomas after targeted therapy, which may harbor co-occurring BRAF and NRAS mutations [3]. This evidence concerns the gene BRAF and melanoma.